Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 4Genitourinary 3Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Isotretinoin × Genitourinary × Clear all
NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting
28 enrolled
Genitourinary

Kidney Neoplasms, Wilms Tumor

NCT00324740 2021-02-23

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
14 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell

NCT00003585 2013-12-10

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

University of New Mexico

Phase 1/2 Completed
35 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡